HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?-Reference-Cited by-同舟云学术

HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?

Author:

Wong Daniel D.¹,de Boer W. Bastiaan¹²,Platten Michael A.¹,Jo Vickie Y.³⁴,Cibas Edmund S.³⁴,Kumarasinghe M. Priyanthi¹²

Affiliation:

1. Department of Anatomical Pathology, PathWest Laboratory Medicine; QEII Medical Centre; Hospital Avenue Nedlands Western Australia

2. School of Pathology and Laboratory Medicine; University of Western Australia; Crawley Western Australia

3. Department of Pathology; Brigham and Women's Hospital; Boston Massachusetts

4. Department of Pathology; Harvard Medical School; Boston Massachusetts

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

Reference23 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

3. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer;Yonemura;Cancer Res,1991

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献